Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Zhang QY, et al
People who need quick results for a specific event or milestone
Direct head-to-head data against tirzepatide showed CagriSema underperforming the highest tirzepatide dose at 84 weeks meaning monotherapy claims of comparable efficacy are not supported by current Phase 3 evidence
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
US$ 21.31
US$ 28.14
US$ 26.84
